BRPI0508352A - ésteres derivados de reìna e seus usos terapêuticos - Google Patents

ésteres derivados de reìna e seus usos terapêuticos

Info

Publication number
BRPI0508352A
BRPI0508352A BRPI0508352-4A BRPI0508352A BRPI0508352A BR PI0508352 A BRPI0508352 A BR PI0508352A BR PI0508352 A BRPI0508352 A BR PI0508352A BR PI0508352 A BRPI0508352 A BR PI0508352A
Authority
BR
Brazil
Prior art keywords
alkyl
reine
therapeutic uses
derived esters
optionally substituted
Prior art date
Application number
BRPI0508352-4A
Other languages
English (en)
Inventor
Andrew Douglas Baxter
Andrea Walmsley
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of BRPI0508352A publication Critical patent/BRPI0508352A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C66/00—Quinone carboxylic acids
    • C07C66/02—Anthraquinone carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

éSTERES DERIVADOS DE REìNA E SEUS USOS TERAPêUTICOS. Compostos que podem ter atividade antiinflamatória são de fórmula geral (I) : onde X~ 1~ é H ou COR~ 1~, e X~ 2~ é H ou COR~ 2~ mas X~ 1~ e X~ 2~ não são ambos H; R~ 1~ e R~ 2~ são os mesmos ou diferentes e são, cada um, alquila C~ 1-4~ substituída com R~ 3~, ou um anel de quatro a sete membros que pode ser opcionalmente substituído com R~ 8~ e pode conter um ou mais heteroátomos adicionais selecionados de O, S(O)~ n~ e NR~ 9~; R~ 3~ é F, CF~ 3~, OR~ 4~, NR~ 5~R~ 6~ ou S(O)~ n~R~ 7~; R~ 4~, R~ 5~ e R~ 6~ são os mesmos ou diferentes e são cada um H ou alquila C~ 1-4~ opcionalmente substituída com R~ 3~, ou NR~ 5~R~ 6~ é um anel heterocicloalquila C~ 4-6~ contendo um ou mais heteroátomos selecionados de O, NR~ 8~ e S(O)~ n~; cada n é 0-2; R~ 7~ é alquila C~ 1-4~; R~ 8~ é definido por R~ 3~ ou alquila C~ 1-4~ opcionalmente substituida com R~ 3~ ou halogênio; e R~ 9~ é H ou alquila C~ 1-4~; ou um seu sal, solvato ou hidrato.
BRPI0508352-4A 2004-03-04 2005-03-04 ésteres derivados de reìna e seus usos terapêuticos BRPI0508352A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0404953.2A GB0404953D0 (en) 2004-03-04 2004-03-04 Pro-drugs
PCT/GB2005/000832 WO2005085170A1 (en) 2004-03-04 2005-03-04 Ester derivatives of rhein and their therapeutic use

Publications (1)

Publication Number Publication Date
BRPI0508352A true BRPI0508352A (pt) 2007-07-31

Family

ID=32088751

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508352-4A BRPI0508352A (pt) 2004-03-04 2005-03-04 ésteres derivados de reìna e seus usos terapêuticos

Country Status (14)

Country Link
US (1) US7728035B2 (pt)
EP (1) EP1723097A1 (pt)
JP (1) JP4478713B2 (pt)
KR (1) KR20070010142A (pt)
CN (1) CN1938258A (pt)
AU (1) AU2005219642B2 (pt)
BR (1) BRPI0508352A (pt)
CA (1) CA2558082A1 (pt)
GB (1) GB0404953D0 (pt)
IL (1) IL177752A0 (pt)
MX (1) MXPA06010058A (pt)
NO (1) NO20064031L (pt)
WO (1) WO2005085170A1 (pt)
ZA (1) ZA200607386B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622479D0 (en) * 2006-11-10 2006-12-20 Sosei R & D Ltd Novel salts and their therapeutic use
CN101735271A (zh) * 2008-11-05 2010-06-16 上海慈瑞医药科技有限公司 具有趋骨性的双膦酸大黄酸醚衍生物及其制备方法
CN102225896B (zh) * 2011-04-07 2013-10-30 栗进才 大黄酸的醚衍生物以及它们的治疗用途
CN102552430A (zh) * 2011-12-03 2012-07-11 彭旦明 一种抑制瘢痕的有效部位群及其制备方法
CN102603575B (zh) * 2012-01-04 2014-08-13 丛晓东 大精酸共晶物、其制备方法、纯化方法及其在制备治疗糖尿病并发症药物中的应用
AU2013290277B2 (en) * 2012-07-10 2016-07-21 Children's Healthcare Of Atlanta, Inc. Anthraquinone analogs and methods of making and using thereof
CN104547207A (zh) * 2015-01-29 2015-04-29 陈文斌 消除陈旧性疤痕的中药外敷制剂及制备方法
CN108349867B (zh) * 2015-08-17 2021-03-09 安成生物科技股份有限公司 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
CN106619503B (zh) * 2016-09-23 2019-09-13 辽宁大学 一种大黄酸酰胺类衍生物纳米混悬剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) * 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
JPS58225015A (ja) * 1983-02-25 1983-12-27 プロツタ−・エス・ピ−・エ− 硬化症治療薬
IT1283772B1 (it) * 1996-07-31 1998-04-30 Medidom Lab Procedimento per la preparazione di reina e diacereina
FR2757397B1 (fr) 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree

Also Published As

Publication number Publication date
EP1723097A1 (en) 2006-11-22
JP4478713B2 (ja) 2010-06-09
IL177752A0 (en) 2006-12-31
AU2005219642B2 (en) 2009-04-23
CA2558082A1 (en) 2005-09-15
US20070185036A1 (en) 2007-08-09
MXPA06010058A (es) 2007-05-10
AU2005219642A1 (en) 2005-09-15
WO2005085170A1 (en) 2005-09-15
JP2007526293A (ja) 2007-09-13
CN1938258A (zh) 2007-03-28
ZA200607386B (en) 2008-05-28
GB0404953D0 (en) 2004-04-07
NO20064031L (no) 2006-09-15
KR20070010142A (ko) 2007-01-22
US7728035B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
EA201001518A1 (ru) Производные 1-гетероциклил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве модуляторов pde9a
BR112013010564A2 (pt) compostos heterocíclicos e usos desses
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
SV2010003654A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos
BRPI0412527A (pt) composto, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica, e, processo para preparar um composto.
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
PA8604301A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
ECSP088293A (es) Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
BR112012011310A2 (pt) compostos derivados de 8-azabiciclo[3.2.1]octano-8-carboxamida, seu medicamento, seu agente terapêutico e seu uso
BR0307248A (pt) Derivado de pirrolo[3,2-d]pirimidina ou um sal medicinalmente aceitável deste, composição farmacêutica, inibidor de gsk-3, e, agente terapêutico ou profilático para uma doença associada com a gsk-3
BR0316950A (pt) Derivados de indazol como antagonistas de crf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.